THROMBOCYTOSIS AS A PROGNOSTIC FACTOR IN ENDOMETRIAL CARCINOMA

We reviewed the prevalence of thrombocytosis (platelet count greater t han or equal to 400,000/mu L) and its association with outcome in 135 consecutive endometrial carcinoma patients and compared the platelet c ount with other prognostic factors. Nineteen of 135 patients (14%) had thrombocytosis. Thrombocytosis was significantly more frequent in adv anced disease (stage II-IV), unfavorable grade (G2 and G3), deep myome trial invasion, and lymph-vascular space invasion. The overall 5-year survival rate was 92%. The 5-year survival rate of the 19 patients wit h thrombocytosis was significantly worse than that of the patients wit hout thrombocytosis (61 vs 96%, P < 0.0001). The recurrence rate was s ignificantly higher in patients with thrombocytosis than in those with a platelet count <400,000/mu L (7 vs 32%, P < 0.005). In a multivaria te analysis, thrombocytosis continued to be a predictor of worse progn osis. In conclusion, we found thrombocytosis to be a prognostic factor for survival in patients with endometrial carcinoma. (C) 1998 Academi c Press.